drugset / Trial / NCT06363630

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

NCT06363630

Phase 1 Completed 35 enrolled Celgene Corporation
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug-drug interaction (DDI) potential of coadministration of itraconazole or rifampin on the single dose drug levels of golcadomide.

Timeline

Start
2024-04-23
Primary completion
2024-08-29
Completion
2024-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Golcadomide Other / unclassified
Subject Itraconazole Small molecule
Subject Rifampin Small molecule

Indications

No indication recorded.